866-997-4948(US-Canada Toll Free)

Gliosarcoma - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 215 Pages

Gliosarcoma - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gliosarcoma - Pipeline Review, H2 2017, provides an overview of the Gliosarcoma (Oncology) pipeline landscape.

Gliosarcoma is a type of brain tumor that originates from glial cells. The tumor grows rapidly and symptom will vary depending on the exact location and size of the tumor. Most likely they may be headache, vomiting, cognitive problems, and drowsiness. Treatment of brain tumors depends upon the type and staging of the tumor, its size and position in the brain, as well as the age and other health problems of patient.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gliosarcoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Gliosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gliosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gliosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 1, 14 and 12 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Gliosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gliosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Gliosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gliosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gliosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gliosarcoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gliosarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gliosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Gliosarcoma - Overview 8
Gliosarcoma - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 16
Gliosarcoma - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 20
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Gliosarcoma - Companies Involved in Therapeutics Development 27
AbbVie Inc 27
Agenus Inc 27
Bristol-Myers Squibb Co 28
Celgene Corp 28
DelMar Pharmaceuticals Inc 29
ERC Belgium SA 29
Ipsen SA 30
Kite Pharma Inc 30
Merck & Co Inc 31
Millennium Pharmaceuticals Inc 31
NewLink Genetics Corp 32
Northwest Biotherapeutics Inc 32
Novartis AG 33
Nuo Therapeutics Inc 33
Gliosarcoma - Drug Profiles 34
ALD-451 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
alisertib - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
avadomide hydrochloride - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Cellular Immunotherapy to Target CD3 and EGFR for Oncology - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Cellular Immunotherapy to Target EGFR vIII for Glioblastoma Multiforme and Gliosarcoma - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
dasatinib - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
DCVax-L - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
depatuxizumab mafodotin - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
dianhydrogalactitol - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
DNX-2401 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
ERC-1671 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
flucytosine + TBio-01 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
G-200 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
indoximod - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
irinotecan hydrochloride - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
irinotecan hydrochloride + TBio-02 - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
lonafarnib - Drug Profile 111
Product Description 111
Mechanism Of Action 111
R&D Progress 111
M-032 - Drug Profile 114
Product Description 114
Mechanism Of Action 114
R&D Progress 114
marizomib - Drug Profile 115
Product Description 115
Mechanism Of Action 115
R&D Progress 115
p28 - Drug Profile 120
Product Description 120
Mechanism Of Action 120
R&D Progress 120
pazopanib hydrochloride - Drug Profile 122
Product Description 122
Mechanism Of Action 122
R&D Progress 122
pembrolizumab - Drug Profile 131
R&D Progress 132
relatlimab - Drug Profile 196
Product Description 196
Mechanism Of Action 196
R&D Progress 196
RRX-001 - Drug Profile 198
Product Description 198
Mechanism Of Action 198
R&D Progress 198
sapanisertib - Drug Profile 201
Product Description 201
Mechanism Of Action 201
R&D Progress 201
SGT-53 - Drug Profile 205
Product Description 205
Mechanism Of Action 205
R&D Progress 205
TG-02 - Drug Profile 207
Product Description 207
Mechanism Of Action 207
R&D Progress 207
urelumab - Drug Profile 210
Product Description 210
Mechanism Of Action 210
R&D Progress 210
Gliosarcoma - Dormant Projects 213
Appendix 214
Methodology 214
Coverage 214
Secondary Research 214
Primary Research 214
Expert Panel Validation 214
Contact Us 214
Disclaimer 215

List of Tables
Number of Products under Development for Gliosarcoma, H2 2017 9
Number of Products under Development by Companies, H2 2017 11
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 12
Number of Products under Development by Universities/Institutes, H2 2017 13
Products under Development by Companies, H2 2017 14
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15
Products under Development by Universities/Institutes, H2 2017 16
Number of Products by Stage and Target, H2 2017 18
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 19
Number of Products by Stage and Mechanism of Action, H2 2017 21
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 22
Number of Products by Stage and Route of Administration, H2 2017 24
Number of Products by Stage and Molecule Type, H2 2017 26
Gliosarcoma - Pipeline by AbbVie Inc, H2 2017 27
Gliosarcoma - Pipeline by Agenus Inc, H2 2017 28
Gliosarcoma - Pipeline by Bristol-Myers Squibb Co, H2 2017 28
Gliosarcoma - Pipeline by Celgene Corp, H2 2017 29
Gliosarcoma - Pipeline by DelMar Pharmaceuticals Inc, H2 2017 29
Gliosarcoma - Pipeline by ERC Belgium SA, H2 2017 29
Gliosarcoma - Pipeline by Ipsen SA, H2 2017 30
Gliosarcoma - Pipeline by Kite Pharma Inc, H2 2017 30
Gliosarcoma - Pipeline by Merck & Co Inc, H2 2017 31
Gliosarcoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2017 31
Gliosarcoma - Pipeline by NewLink Genetics Corp, H2 2017 32
Gliosarcoma - Pipeline by Northwest Biotherapeutics Inc, H2 2017 32
Gliosarcoma - Pipeline by Novartis AG, H2 2017 33
Gliosarcoma - Pipeline by Nuo Therapeutics Inc, H2 2017 33
Gliosarcoma - Dormant Projects, H2 2017 213

List of Figures
Number of Products under Development for Gliosarcoma, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Number of Products by Top 10 Targets, H2 2017 17
Number of Products by Stage and Top 10 Targets, H2 2017 17
Number of Products by Top 10 Mechanism of Actions, H2 2017 20
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 20
Number of Products by Routes of Administration, H2 2017 23
Number of Products by Stage and Routes of Administration, H2 2017 23
Number of Products by Molecule Types, H2 2017 25
Number of Products by Stage and Molecule Types, H2 2017 25

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *